Skip to main content
Lippincott Open Access logoLink to Lippincott Open Access
. 2026 Jul 27;44(24):2361. doi: 10.1200/JCO-26-01800

Erratum: High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis

Matthew R Wilson, Katharine L Lewis, Amy A Kirkwood, Kate Cwynarski, Chan Y Cheah, Tarec C El-Galaly, Diego Villa, Kerry J Savage, Paola Ghione, Sabela Bobillo, Karin E Smedby, Sara Harrysson, Marek Trneny, Magdalena Klanova, Robert Puckrin, Christopher P Fox, Mark Bishton, Gita Thanarajasingam, Nicole Wong Doo, Greg Hapgood, Carole Soussain, Sylvain Choquet, Michael Dickinson, Dipti Talaulikar, Sanjay de Mel, Gavin Preston, Matthew Ahearne, Eliza A Hawkes, Elisabeth Schorb, Aline Clavert, Matthew Ku, Anna Guidetti, Mayur Narkhede, Teresa Calimeri, Eric Durot, Jeffrey Smith, Loïc Renaud, Pamela McKay, Toby A Eyre
PMCID: PMC13489772  PMID: 42507971

The article by Wilson et al entitled “High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis” (Journal of Clinical Oncology 10.1200/JCO-26-00947) was published online June 11, 2026, with an error.

In Table 2, the row entitled “Number of HD-MTX cycles ≥3 mg/m2, No. (%)” is intended to read “Number of HD-MTX cycles ≥3 g/m2, No. (%).”

This has been corrected as of July 27, 2026. The authors apologize for the error.


Articles from Journal of Clinical Oncology are provided here courtesy of Wolters Kluwer Health

RESOURCES